Compare Cassava Sciences Inc (FLNA) vs UiPath Inc (PATH) Price & Performance

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.

UiPath (PATH) trades at $11.94, up 0.76% with a bullish technical outlook and strong support at $11. The company shows improving fundamentals with revenue growing from $1.43B in 2025 to projected $1.7B in 2026, while transitioning from losses to profitability. Recent earnings show mixed results with Q2 2026 expectations at $0.15 EPS. The stock trades below analyst consensus target of $13.33, representing potential upside from current levels.

PATH presents a compelling turnaround story with improving profitability and strong gross margins above 80%. Key risks include execution challenges in AI monetization and competitive pressures in enterprise automation. The 25% upside to consensus target and improving cash flow trends support a constructive outlook, though investors should monitor Q2 earnings delivery and enterprise adoption of Maestro AI capabilities.